초록

The invention provides methods and reagents useful for detecting anti-drug antibodies of IgE isotype to therapeutic anti-IgE antibodies, and methods for assessing risk of anaphylaxis to administration of a therapeutic anti-IgE antibody.

대표청구항 ▼

1. A method for detecting an anti-drug antibody of IgE isotype that may be present in a sample from a human patient, wherein variable regions of the anti-drug antibody specifically bind to a therapeutic anti-IgE antibody, comprising the steps of: (a) contacting the sample with a mutant of the therap

1. A method for detecting an anti-drug antibody of IgE isotype that may be present in a sample from a human patient, wherein variable regions of the anti-drug antibody specifically bind to a therapeutic anti-IgE antibody, comprising the steps of: (a) contacting the sample with a mutant of the therapeutic antibody comprising one, two, three, four, five, or six amino acid mutations in complementarity determining region (CDR) sequences of a heavy or light chain of the therapeutic anti-IgE antibody, wherein relative binding affinity of the mutant therapeutic antibody to an Fc region of human IgE is about 10% or less of relative binding affinity of the therapeutic anti-IgE antibody to said Fc region of human IgE; and(b) detecting specific binding of the anti-drug antibody of IgE isotype in the sample to the mutant therapeutic antibody, wherein the detection of the specific binding indicates presence or level of the anti-drug antibody of IgE isotype in the patient. 2. The method of claim 1, wherein the relative binding affinity of the mutant therapeutic antibody to the human IgE is about 5% or less of the relative binding affinity of the therapeutic anti-IgE antibody to the human IgE. 3. The method of claim 1, wherein the relative binding affinity of the mutant therapeutic antibody to the human IgE is about 2.5% or less of the relative binding affinity of the therapeutic anti-IgE antibody to the human IgE. 4. The method of claim 1, wherein the relative binding affinity of the mutant therapeutic antibody to the human IgE is about 1% or less of the relative binding affinity of the therapeutic anti-IgE antibody to the human IgE. 5. The method of claim 1, wherein the relative binding affinity is measured by comparing the binding to the human IgE in an enzyme-linked immunosorbent assay (ELISA). 6. The method of claim 1, wherein the sample is human serum or plasma from the human patient or a dilution thereof. 7. The method of claim 6, wherein the serum or plasma sample contains the therapeutic antibody. 8. The method of claim 6, wherein the serum or plasma sample does not contain the therapeutic antibody. 9. The method of claim 1, wherein the therapeutic anti-IgE antibody is omalizumab. 10. The method of claim 1, wherein the therapeutic anti-IgE antibody is omalizumab, and the mutant therapeutic antibody comprises one, two, or three amino acid mutations in the first CDR sequence of the light chain of omalizumab. 11. The method of claim 10, wherein the mutant therapeutic antibody comprises the heavy chain amino acid sequence of SEQ ID NO:2 and the light chain amino acid sequence of SEQ ID NO: 1, wherein Asp amino acid residues at positions 30, 32, and 34 are substituted in the light chain. 12. The method of claim 10, wherein the mutant therapeutic antibody comprises the heavy chain amino acid sequence of SEQ ID NO:2 and the light chain amino acid sequence of SEQ ID NO:1 with amino acid substitutions of Asp to Ala at positions 30, 32, and 34. 13. The method of claim 1, further comprising a step of comparing the binding of the anti-drug antibodies of the IgE isotype to the mutant therapeutic antibody detected in step b) to a reference. 14. The method of claim 13, wherein the reference is detected binding between the mutant therapeutic antibody and a control antibody. 15. The method of claim 14, wherein the control antibody is a positive control antibody that binds both the therapeutic anti-IgE antibody and the mutant therapeutic antibody, wherein difference between relative binding affinities of the positive control antibody to the therapeutic anti-IgE antibody and to the mutant therapeutic antibody is less than 50%. 16. The method of claim 15, wherein the positive control antibody comprises a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:7 and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:8. 17. A method for detecting an anti-drug antibody of IgE isotype that may be present in a sample from a human patient, wherein variable regions of the anti-drug antibody specifically bind to a therapeutic anti-IgE antibody, comprising the steps of: (a) contacting the sample with a mutant of the therapeutic antibody comprising one, two, three, four, five, or six amino acid mutations in complementarity determining region (CDR) sequences of a heavy or light chain of the therapeutic anti-IgE antibody, wherein potency of the mutant therapeutic antibody to human IgE is about 10% or less of potency of the therapeutic anti-IgE antibody to said human IgE; and(b) detecting specific binding of the anti-drug antibody of IgE isotype in the sample to the mutant therapeutic antibody, wherein the detection of the specific binding indicates presence or level of the anti-drug antibody of IgE isotype in the patient. 18. The method of claim 1 or claim 17, wherein the mutant therapeutic antibody is captured to a surface. 19. The method of claim 18, wherein the mutant therapeutic antibody is captured by direct immobilization to the surface. 20. The method of claim 18, wherein the mutant therapeutic antibody is labeled and is captured to the surface through a capture agent that specifically binds to the label, wherein the capture agent is immobilized to the surface. 21. The method of claim 20, wherein the label is biotin and the capture agent is streptavidin. 22. The method of claim 20, wherein the label is digoxigenin and the capture agent is an anti-digoxigenin antibody. 23. The method of claim 1 or claim 17, wherein the sample is contacted with the mutant therapeutic antibody that is captured to a surface. 24. The method of claim 1 or claim 17, wherein the sample is contacted with the mutant therapeutic antibody before the mutant therapeutic antibody is captured to a surface. 25. The method of claim 1 or claim 17, wherein the binding of the anti-drug antibodies of the IgE isotype to the mutant therapeutic antibody is detected with a detecting agent. 26. The method of claim 25, wherein the detecting agent is an FcεRIα polypeptide that binds to an Fc region of a human IgE. 27. The method of claim 26, wherein the FcεRIα polypeptide comprises an extracellular domain of an FcεRIα subunit. 28. The method of claim 27, wherein the FcεRIα polypeptide comprises an extracellular domain of an FcεRIα subunit fused to an IgG constant region. 29. The method of claim 26, wherein the FcεRIα polypeptide is labeled. 30. The method of claim 29, wherein the label on the FcεRIα polypeptide is selected from the group consisting of biotin, digoxigenin, ruthenium, a radiologic label, a photoluminescent label, a chemiluminescent label, a fluorescent label, an electrochemiluminescent label, and an enzyme label. 31. The method of claim 29, wherein the label on the FcεRIα polypeptide is detected by a second detecting agent that specifically binds to the label on the FcεRIα polypeptide. 32. A method for detecting an anti-drug antibody of IgE isotype that may be present in a sample from a human patient, wherein variable regions of the anti-drug antibody specifically bind to a therapeutic anti-IgE antibody, comprising the steps of: (a) contacting the sample that may contain the anti-drug antibody with (i) a mutant of the therapeutic antibody and (ii) an FcεRIα polypeptide that binds to an Fc region of a human IgE, wherein the mutant therapeutic antibody comprises one, two, three, four, five, or six amino acid mutations in complementarity determining region (CDR) sequences of a heavy or light chain of the therapeutic anti-IgE antibody, and wherein relative binding affinity of the mutant therapeutic antibody to an Fc region of human IgE is about 10% or less of relative binding affinity of the therapeutic anti-IgE antibody to said Fc region of human IgE; wherein the sample contains whole blood, serum or plasma from the human patient;(b) capturing the contacted mutant therapeutic antibody to a surface; and(c) detecting specific binding of the anti-drug antibody of IgE isotype in the sample to the mutant therapeutic antibody, wherein the detection of the specific binding indicates presence or level of the anti-drug antibody of IgE isotype in the patient. 33. The method of claim 32, wherein excess amount of FcεRIα polypeptide is contacted with the sample in step (a). 34. The method of claim 33, wherein at least about 10-fold excess of FcεRIα polypeptide is contacted with the sample in step (a). 35. The method of claim 32, wherein the FcεRIα polypeptide comprises an extracellular domain of an FcεRIα subunit. 36. The method of claim 32, wherein the mutant therapeutic antibody is labeled and is captured to the surface by a surface-immobilized capture agent that specifically binds to the label. 37. The method of claim 36, wherein the label is biotin and the surface is coated with streptavidin as the capture agent. 38. The method of claim 32, wherein the binding of the anti-drug antibody of the IgE isotype to the mutant therapeutic antibody is detected by a labeled anti-human IgE antibody. 39. The method of claim 32, wherein the FcεRIα polypeptide is labeled and the binding of the anti-drug antibody of the IgE isotype to the mutant therapeutic antibody is detected by a detecting agent that specifically binds to the label on the FcεRIα polypeptide. 40. The method of claim 1, 17, or 32, wherein the mutant therapeutic antibody comprises one, two, three, four, five, or six amino acid mutations in the CDR sequences of the heavy and light chain of the therapeutic anti-IgE antibody.